Effect of Mepolizumab on Severe Eosinophilic Asthma

UnknownOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

March 1, 2025

Conditions
AsthmaEosinophilic Asthma
Interventions
DRUG

Mepolizumab 100 MG

Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.

Trial Locations (5)

15006

NOT_YET_RECRUITING

Complexo Hospitalario Universitario A Coruña, A Coruña

15405

RECRUITING

Complejo Hospitalario Universitario de Ferrol, Ferrol

15706

NOT_YET_RECRUITING

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

32005

RECRUITING

Complexo Hospitalario Universitario de Ourense, Ourense

36211

NOT_YET_RECRUITING

Hospital Povisa - Grupo Ribera Salud, Vigo

Sponsors

Collaborators (1)

All Listed Sponsors
lead

Hospital Clinico Universitario de Santiago

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

NCT04641741 - Effect of Mepolizumab on Severe Eosinophilic Asthma | Biotech Hunter | Biotech Hunter